Regulation - Pharmaceutical, Janssen Pharmaceutica


Popular Filters

Janssen submits NDA for "breakthrough" leukemia and lymphoma drug ibrutinib


Janssen Pharmaceuticals, a unit of US health care giant Johnson & Johnson (NYSE: JNJ), has submitted…

ibrutinibJanssen PharmaceuticaJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

US FDA clears Bayer/Johnson & Johnson’s Xarelto for stroke risk reduction in AF patients


In what was much-awaited good news for German drug major Bayer (BAY: DE), its US subsidiary announced…

BayerCardio-vascularJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Johnson & Johnson’s telaprevir approved in Europe for genotype-1 chronic hepatitis C


The European Commission has approved Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Incivo (telaprevir),…

Anti-viralsEuropeIncivekIncivoJanssen PharmaceuticaJohnson & JohnsonPharmaceuticalRegulationtelaprivirVertex

Back to top